ATX

AMPLIA THERAPEUTICS

0.17

0.01+2.94%

Closed16:10 01/09 AEDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.170/0.170

TODAY RANGE0.168-0.180

VOL2.89M

MARKET CAP89.79M

52 WEEK RANGE0.049-0.425

AVG VOL (3M)1.32M

% TURNOVER0.56%

TURNOVER503.38K

P/E (TTM)-8.5784

% RANGE7.35%

EPS(TTM)-0.0204

P/E(FORWARD)--

P/B2.091

BVPS0.084

DIVIDEND--

P/S18.04

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP76.11M

SHARES OUTSTANDING513.07M

NEXT EARNINGS--

FREE FLOAT434.91M

LOT SIZE1

EX-DATE--

News

Press Releases

Financial Reports

Profile

ASX·1d ago
ACCENT Data Presented at 2026 ASCO GI Cancer Symposium
ASX·12/18/2025 21:27
Amplia Enters 2nd Agreement with Drug Screening Co Next Bio
ASX·12/11/2025 08:58
Additional Confirmed Response Reported-Investor Presentation
ASX·12/04/2025 00:00
AMPLIA THERAPEUTICS LIMITED Prelim Q2
ASX·12/02/2025 21:32
Key narmafotinib Patent Granted in the US
ASX·11/27/2025 05:45
Half Yearly Report and Accounts
ASX·11/19/2025 17:01
Positive Response from US FDA to Amplia's Type D Meeting
ASX·11/10/2025 05:42
Notification regarding unquoted securities - ATX
ASX·10/30/2025 21:19
Amplia Commences Trading on U.S. OTCQB Venture Market
ASX·10/28/2025 22:05
Quarterly Activities/Appendix 4C Cash Flow Report
ASX·10/27/2025 22:15
Amplia Receives R&D Tax Rebate Totalling $3.77 Million
ASX·10/16/2025 23:35
Amplia Therapeutics to Significantly Expand U.S. Presence
ASX·10/08/2025 21:27
ADDITIONAL RESPONSES IN ACCENT PANCREATIC CANCER TRIAL
ASX·10/07/2025 22:49
Notification of cessation of securities - ATX
ASX·09/29/2025 22:37
Patent Allowance for Key Narmafotinib Patent in US

Same Industry

Name/Symbol

Change%

Price

No data yet, let's see others

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.